(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 March 2019 (14.03.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/051084 A1

(51) International Patent Classification:
A61K 45/06 (2006.01) *A61K 31/497* (2006.01)
A61K 9/00 (2006.01) *A61P 35/00* (2006.01)
A61K 31/4427 (2006.01)

(21) International Application Number:
PCT/US2018/049744

(22) International Filing Date:
06 September 2018 (06.09.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/555,400	07 September 2017 (07.09.2017)	US
62/558,255	13 September 2017 (13.09.2017)	US
62/653,831	06 April 2018 (06.04.2018)	US
62/681,001	05 June 2018 (05.06.2018)	US

(71) Applicant: **REVOLUTION MEDICINES, INC.** [US/US]; 700 Saginaw Drive, Redwood City, California 94063 (US).

(72) Inventors: **NICHOLS, Robert J.**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US). **GOLDSMITH, Mark A.**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US). **SCHULZE, Christopher**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US). **SMITH, Jacqueline**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US). **WILDES, David E.**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US). **KELSEY, Stephen**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US). **SINGH, Mallika**; c/o Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, California 94063 (US).

(74) Agent: **NUDELMAN, Aaron S.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER

FIG. 21A



(57) Abstract: The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.

WO 2019/051084 A1